JP4797349B2 - Method of stabilizing reagent using vitamin B6 enzyme and reagent - Google Patents
Method of stabilizing reagent using vitamin B6 enzyme and reagent Download PDFInfo
- Publication number
- JP4797349B2 JP4797349B2 JP2004264473A JP2004264473A JP4797349B2 JP 4797349 B2 JP4797349 B2 JP 4797349B2 JP 2004264473 A JP2004264473 A JP 2004264473A JP 2004264473 A JP2004264473 A JP 2004264473A JP 4797349 B2 JP4797349 B2 JP 4797349B2
- Authority
- JP
- Japan
- Prior art keywords
- reagent
- enzyme
- vitamin
- tyrosine
- coenzyme
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000003153 chemical reaction reagent Substances 0.000 title claims description 75
- 238000000034 method Methods 0.000 title claims description 17
- 230000000087 stabilizing effect Effects 0.000 title claims description 7
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 title description 84
- 102000004190 Enzymes Human genes 0.000 title description 67
- 108090000790 Enzymes Proteins 0.000 title description 67
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 title description 42
- 235000019158 vitamin B6 Nutrition 0.000 title description 42
- 239000011726 vitamin B6 Substances 0.000 title description 42
- 229940011671 vitamin b6 Drugs 0.000 title description 42
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 26
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 24
- 235000007682 pyridoxal 5'-phosphate Nutrition 0.000 claims description 18
- 239000011589 pyridoxal 5'-phosphate Substances 0.000 claims description 18
- NGVDGCNFYWLIFO-UHFFFAOYSA-N pyridoxal 5'-phosphate Chemical compound CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O NGVDGCNFYWLIFO-UHFFFAOYSA-N 0.000 claims description 17
- 108010035075 Tyrosine decarboxylase Proteins 0.000 claims description 14
- 229960001327 pyridoxal phosphate Drugs 0.000 claims description 14
- 238000003860 storage Methods 0.000 claims description 10
- 239000005515 coenzyme Substances 0.000 description 37
- 229960004441 tyrosine Drugs 0.000 description 24
- 230000000694 effects Effects 0.000 description 16
- RLFWWDJHLFCNIJ-UHFFFAOYSA-N 4-aminoantipyrine Chemical compound CN1C(C)=C(N)C(=O)N1C1=CC=CC=C1 RLFWWDJHLFCNIJ-UHFFFAOYSA-N 0.000 description 10
- 238000002835 absorbance Methods 0.000 description 10
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 8
- 238000005259 measurement Methods 0.000 description 8
- -1 2-hydroxy-3-sulfopropyl Chemical group 0.000 description 6
- 102000003992 Peroxidases Human genes 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 230000000052 comparative effect Effects 0.000 description 6
- 108040007629 peroxidase activity proteins Proteins 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 102000010909 Monoamine Oxidase Human genes 0.000 description 5
- 108010062431 Monoamine oxidase Proteins 0.000 description 5
- DZGWFCGJZKJUFP-UHFFFAOYSA-N Tyramine Natural products NCCC1=CC=C(O)C=C1 DZGWFCGJZKJUFP-UHFFFAOYSA-N 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 238000004040 coloring Methods 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- ZMJGSOSNSPKHNH-UHFFFAOYSA-N pyridoxamine 5'-phosphate Chemical compound CC1=NC=C(COP(O)(O)=O)C(CN)=C1O ZMJGSOSNSPKHNH-UHFFFAOYSA-N 0.000 description 4
- 235000008974 pyridoxamine 5'-phosphate Nutrition 0.000 description 4
- 239000011580 pyridoxamine 5'-phosphate Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 229960003732 tyramine Drugs 0.000 description 4
- DZGWFCGJZKJUFP-UHFFFAOYSA-O tyraminium Chemical compound [NH3+]CCC1=CC=C(O)C=C1 DZGWFCGJZKJUFP-UHFFFAOYSA-O 0.000 description 4
- ZTQGWROHRVYSPW-UHFFFAOYSA-N 3-(n-ethyl-3-methylanilino)-2-hydroxypropane-1-sulfonic acid Chemical compound OS(=O)(=O)CC(O)CN(CC)C1=CC=CC(C)=C1 ZTQGWROHRVYSPW-UHFFFAOYSA-N 0.000 description 3
- 108010025076 Holoenzymes Proteins 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 238000012423 maintenance Methods 0.000 description 3
- 238000000691 measurement method Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000001590 oxidative effect Effects 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- IPRPPFIAVHPVJH-UHFFFAOYSA-N (4-hydroxyphenyl)acetaldehyde Chemical compound OC1=CC=C(CC=O)C=C1 IPRPPFIAVHPVJH-UHFFFAOYSA-N 0.000 description 2
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 2
- HSJKGGMUJITCBW-UHFFFAOYSA-N 3-hydroxybutanal Chemical compound CC(O)CC=O HSJKGGMUJITCBW-UHFFFAOYSA-N 0.000 description 2
- 108010006591 Apoenzymes Proteins 0.000 description 2
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 2
- 108090000489 Carboxy-Lyases Proteins 0.000 description 2
- 239000006173 Good's buffer Substances 0.000 description 2
- SEQKRHFRPICQDD-UHFFFAOYSA-N N-tris(hydroxymethyl)methylglycine Chemical compound OCC(CO)(CO)[NH2+]CC([O-])=O SEQKRHFRPICQDD-UHFFFAOYSA-N 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 239000013504 Triton X-100 Substances 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 230000037354 amino acid metabolism Effects 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 239000006172 buffering agent Substances 0.000 description 2
- 239000007979 citrate buffer Substances 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 239000003792 electrolyte Substances 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- PHOLIFLKGONSGY-CSKARUKUSA-N (e)-(3-methyl-1,3-benzothiazol-2-ylidene)hydrazine Chemical compound C1=CC=C2S\C(=N\N)N(C)C2=C1 PHOLIFLKGONSGY-CSKARUKUSA-N 0.000 description 1
- QZTKDVCDBIDYMD-UHFFFAOYSA-N 2,2'-[(2-amino-2-oxoethyl)imino]diacetic acid Chemical compound NC(=O)CN(CC(O)=O)CC(O)=O QZTKDVCDBIDYMD-UHFFFAOYSA-N 0.000 description 1
- IHPYMWDTONKSCO-UHFFFAOYSA-N 2,2'-piperazine-1,4-diylbisethanesulfonic acid Chemical compound OS(=O)(=O)CCN1CCN(CCS(O)(=O)=O)CC1 IHPYMWDTONKSCO-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- AJTVSSFTXWNIRG-UHFFFAOYSA-N 2-[bis(2-hydroxyethyl)amino]ethanesulfonic acid Chemical compound OCC[NH+](CCO)CCS([O-])(=O)=O AJTVSSFTXWNIRG-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- LVQFQZZGTZFUNF-UHFFFAOYSA-N 2-hydroxy-3-[4-(2-hydroxy-3-sulfonatopropyl)piperazine-1,4-diium-1-yl]propane-1-sulfonate Chemical compound OS(=O)(=O)CC(O)CN1CCN(CC(O)CS(O)(=O)=O)CC1 LVQFQZZGTZFUNF-UHFFFAOYSA-N 0.000 description 1
- GGYHRBCDXYNIGD-UHFFFAOYSA-N 3-(3,5-dimethylanilino)propane-1-sulfonic acid Chemical compound CC1=CC(C)=CC(NCCCS(O)(=O)=O)=C1 GGYHRBCDXYNIGD-UHFFFAOYSA-N 0.000 description 1
- DVLFYONBTKHTER-UHFFFAOYSA-N 3-(N-morpholino)propanesulfonic acid Chemical compound OS(=O)(=O)CCCN1CCOCC1 DVLFYONBTKHTER-UHFFFAOYSA-N 0.000 description 1
- BTIDJAQNJLWPTI-UHFFFAOYSA-N 3-(n-ethyl-3,5-dimethoxyanilino)-2-hydroxypropane-1-sulfonic acid Chemical compound OS(=O)(=O)CC(O)CN(CC)C1=CC(OC)=CC(OC)=C1 BTIDJAQNJLWPTI-UHFFFAOYSA-N 0.000 description 1
- NZAVBNVWEPQSBL-UHFFFAOYSA-N 3-(n-ethyl-3,5-dimethoxyanilino)propane-1-sulfonic acid Chemical compound OS(=O)(=O)CCCN(CC)C1=CC(OC)=CC(OC)=C1 NZAVBNVWEPQSBL-UHFFFAOYSA-N 0.000 description 1
- NPROGRQJOGOVDS-UHFFFAOYSA-N 3-(n-ethyl-3,5-dimethylanilino)propane-1-sulfonic acid Chemical compound OS(=O)(=O)CCCN(CC)C1=CC(C)=CC(C)=C1 NPROGRQJOGOVDS-UHFFFAOYSA-N 0.000 description 1
- STBWJPWQQLXSCK-UHFFFAOYSA-N 3-(n-ethyl-3-methoxyanilino)propane-1-sulfonic acid Chemical compound OS(=O)(=O)CCCN(CC)C1=CC=CC(OC)=C1 STBWJPWQQLXSCK-UHFFFAOYSA-N 0.000 description 1
- IBSUMVZKDLDAEK-UHFFFAOYSA-N 3-(n-ethyl-3-methylanilino)propane-1-sulfonic acid Chemical compound OS(=O)(=O)CCCN(CC)C1=CC=CC(C)=C1 IBSUMVZKDLDAEK-UHFFFAOYSA-N 0.000 description 1
- LHZMSRLULDAWLM-UHFFFAOYSA-N 3-(n-ethylanilino)-2-hydroxypropane-1-sulfonic acid Chemical compound OS(=O)(=O)CC(O)CN(CC)C1=CC=CC=C1 LHZMSRLULDAWLM-UHFFFAOYSA-N 0.000 description 1
- HXITYOAFXWBMLL-UHFFFAOYSA-N 3-(n-ethylanilino)propane-1-sulfonic acid Chemical compound OS(=O)(=O)CCCN(CC)C1=CC=CC=C1 HXITYOAFXWBMLL-UHFFFAOYSA-N 0.000 description 1
- NYLUYMWPXIIXDX-UHFFFAOYSA-N 3-(phenylazaniumyl)propane-1-sulfonate Chemical compound OS(=O)(=O)CCCNC1=CC=CC=C1 NYLUYMWPXIIXDX-UHFFFAOYSA-N 0.000 description 1
- 239000007991 ACES buffer Substances 0.000 description 1
- 239000007988 ADA buffer Substances 0.000 description 1
- 108010024957 Ascorbate Oxidase Proteins 0.000 description 1
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 1
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 1
- 239000007992 BES buffer Substances 0.000 description 1
- JDVOFXFRTPHZMW-UHFFFAOYSA-N CCN(CC(CS(=O)(=O)O)O)C1=CC(=CC(=C1C)C)C Chemical compound CCN(CC(CS(=O)(=O)O)O)C1=CC(=CC(=C1C)C)C JDVOFXFRTPHZMW-UHFFFAOYSA-N 0.000 description 1
- 239000008000 CHES buffer Substances 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 108091006149 Electron carriers Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 101710096582 L-tyrosine decarboxylase Proteins 0.000 description 1
- 239000007993 MOPS buffer Substances 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- FSVCELGFZIQNCK-UHFFFAOYSA-N N,N-bis(2-hydroxyethyl)glycine Chemical compound OCCN(CCO)CC(O)=O FSVCELGFZIQNCK-UHFFFAOYSA-N 0.000 description 1
- DBXNUXBLKRLWFA-UHFFFAOYSA-N N-(2-acetamido)-2-aminoethanesulfonic acid Chemical compound NC(=O)CNCCS(O)(=O)=O DBXNUXBLKRLWFA-UHFFFAOYSA-N 0.000 description 1
- MKWKNSIESPFAQN-UHFFFAOYSA-N N-cyclohexyl-2-aminoethanesulfonic acid Chemical compound OS(=O)(=O)CCNC1CCCCC1 MKWKNSIESPFAQN-UHFFFAOYSA-N 0.000 description 1
- JOCBASBOOFNAJA-UHFFFAOYSA-N N-tris(hydroxymethyl)methyl-2-aminoethanesulfonic acid Chemical compound OCC(CO)(CO)NCCS(O)(=O)=O JOCBASBOOFNAJA-UHFFFAOYSA-N 0.000 description 1
- 239000007990 PIPES buffer Substances 0.000 description 1
- 102000009097 Phosphorylases Human genes 0.000 description 1
- 108010073135 Phosphorylases Proteins 0.000 description 1
- 102000004879 Racemases and epimerases Human genes 0.000 description 1
- 108090001066 Racemases and epimerases Proteins 0.000 description 1
- UZMAPBJVXOGOFT-UHFFFAOYSA-N Syringetin Natural products COC1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UZMAPBJVXOGOFT-UHFFFAOYSA-N 0.000 description 1
- 239000007994 TES buffer Substances 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 239000007997 Tricine buffer Substances 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 208000034953 Twin anemia-polycythemia sequence Diseases 0.000 description 1
- 239000007998 bicine buffer Substances 0.000 description 1
- OWMVSZAMULFTJU-UHFFFAOYSA-N bis-tris Chemical compound OCCN(CCO)C(CO)(CO)CO OWMVSZAMULFTJU-UHFFFAOYSA-N 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- 150000005693 branched-chain amino acids Chemical class 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000009615 deamination Effects 0.000 description 1
- 238000006481 deamination reaction Methods 0.000 description 1
- 238000006114 decarboxylation reaction Methods 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 230000000368 destabilizing effect Effects 0.000 description 1
- KCFYHBSOLOXZIF-UHFFFAOYSA-N dihydrochrysin Natural products COC1=C(O)C(OC)=CC(C2OC3=CC(O)=CC(O)=C3C(=O)C2)=C1 KCFYHBSOLOXZIF-UHFFFAOYSA-N 0.000 description 1
- XAZMYOQLNVTRPS-UHFFFAOYSA-L disodium;2-[[4-[2-(1,3-benzothiazol-2-yl)-3-[4-[4-[3-(1,3-benzothiazol-2-yl)-5-[4-[bis(2-sulfonatoethyl)carbamoyl]phenyl]tetrazol-3-ium-2-yl]-3-methoxyphenyl]-2-methoxyphenyl]tetrazol-2-ium-5-yl]benzoyl]-(2-sulfonatoethyl)amino]ethanesulfonate Chemical compound [Na+].[Na+].COC1=CC(C=2C=C(OC)C(=CC=2)N2[N+](=NC(=N2)C=2C=CC(=CC=2)C(=O)N(CCS([O-])(=O)=O)CCS([O-])(=O)=O)C=2SC3=CC=CC=C3N=2)=CC=C1N([N+](=N1)C=2SC3=CC=CC=C3N=2)N=C1C1=CC=C(C(=O)N(CCS([O-])(=O)=O)CCS([O-])(=O)=O)C=C1 XAZMYOQLNVTRPS-UHFFFAOYSA-L 0.000 description 1
- VWWQXMAJTJZDQX-UYBVJOGSSA-N flavin adenine dinucleotide Chemical compound C1=NC2=C(N)N=CN=C2N1[C@@H]([C@H](O)[C@@H]1O)O[C@@H]1CO[P@](O)(=O)O[P@@](O)(=O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C2=NC(=O)NC(=O)C2=NC2=C1C=C(C)C(C)=C2 VWWQXMAJTJZDQX-UYBVJOGSSA-N 0.000 description 1
- 235000019162 flavin adenine dinucleotide Nutrition 0.000 description 1
- 239000011714 flavin adenine dinucleotide Substances 0.000 description 1
- 229940093632 flavin-adenine dinucleotide Drugs 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000006340 racemization Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 239000004328 sodium tetraborate Substances 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- IRQRBVOQGUPTLG-UHFFFAOYSA-M sodium;3-(n-ethyl-3-methylanilino)-2-hydroxypropane-1-sulfonate Chemical compound [Na+].[O-]S(=O)(=O)CC(O)CN(CC)C1=CC=CC(C)=C1 IRQRBVOQGUPTLG-UHFFFAOYSA-M 0.000 description 1
- JUJBNYBVVQSIOU-UHFFFAOYSA-M sodium;4-[2-(4-iodophenyl)-3-(4-nitrophenyl)tetrazol-2-ium-5-yl]benzene-1,3-disulfonate Chemical compound [Na+].C1=CC([N+](=O)[O-])=CC=C1N1[N+](C=2C=CC(I)=CC=2)=NC(C=2C(=CC(=CC=2)S([O-])(=O)=O)S([O-])(=O)=O)=N1 JUJBNYBVVQSIOU-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 150000004992 toluidines Chemical class 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
Landscapes
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Description
本発明は、ビタミンB6酵素を用いた試薬を安定化する技術に関する。 The present invention relates to a technique for stabilizing a reagent using a vitamin B6 enzyme.
ビタミンB6酵素は脱アミノ、脱炭酸、ラセミ化、アルドール開裂などアミノ酸代謝全体に関与する酵素である。例えば本酵素はピリドキサール5’-リン酸(PLP)またはピリドキサミン5’-リン酸(PMP)を補酵素とする。ビタミンB6酵素を用いた試薬として、例えばチロシン測定試薬がある。本試薬は、ビタミンB6酵素であるチロシンデカルボキシラーゼを用い、血清中のチロシンをチラミンに変換し、チラミンにチラミンオキシダーゼを作用させ過酸化水素を生成し、過酸化水素をペルオキシダーゼの存在下、トリンダー試薬、4-アミノアンチピリンを酸化縮合し発色させ吸光度を測定することでチロシン濃度を知るためのものである(例えば、特許文献1参照。)。医療分野では、総分岐鎖アミノ酸とチロシン濃度の比を求めることで、肝疾患の重症度を判定や慢性肝炎から肝硬変の移行期を診断するマーカーとして用いられる。血清中のチロシン濃度は健常者で数十μmol/L程度であり、測定には精度を要する。
本発明は、ビタミンB6酵素の活性発現を安定化し、それを用いた試薬、例えばチロシン測定試薬の安定性、精密性を向上させた安定化法および安定化試薬を提供することを目的とする。 An object of the present invention is to provide a stabilizing method and a stabilizing reagent that stabilize the activity expression of the vitamin B6 enzyme and improve the stability and precision of a reagent using the enzyme, for example, a tyrosine measuring reagent.
本発明は、以下の試薬及び安定化方法に関する。
1.ビタミンB6酵素と該ビタミンB6酵素の補酵素を含む少なくとも2つのパーツを有する試薬であって、ビタミンB6酵素と、ビタミンB6酵素の補酵素を別々のパーツに処方してなる試薬。
2. ビタミンB6酵素がチロシンデカルボキシラーゼである、項1に記載の試薬。
3. 補酵素がピリドキサール5リン酸である、項1に記載の試薬。
4. ビタミンB6酵素を用いた試薬がチロシン測定試薬である、請求項1〜3のいずれかに記載の試薬。
5. ビタミンB6酵素と該酵素の補酵素を含む試薬においてビタミンB6酵素の補酵素を安定化する方法及び試薬であって、貯蔵中の構成として、ビタミンB6酵素とビタミンB6酵素の補酵素を別々に処方することを特徴とする、方法及び試薬。
6. ビタミンB6酵素がチロシンデカルボキシラーゼである、項5に記載の方法及び試薬。
7. 補酵素がピリドキサール5リン酸である、項5に記載の方法及び試薬。
8. ビタミンB6酵素を用いた試薬がチロシン測定試薬である、項5〜7のいずれかに記載の方法及び試薬。
The present invention relates to the following reagents and stabilization methods.
1. A reagent having at least two parts including a vitamin B6 enzyme and a coenzyme of the vitamin B6 enzyme, wherein the vitamin B6 enzyme and the coenzyme of the vitamin B6 enzyme are formulated into separate parts.
2. Item 5. The reagent according to Item 1, wherein the vitamin B6 enzyme is tyrosine decarboxylase.
3. Item 2. The reagent according to Item 1, wherein the coenzyme is pyridoxal 5-phosphate.
4). The reagent according to any one of claims 1 to 3, wherein the reagent using vitamin B6 enzyme is a tyrosine measuring reagent.
5. A method and reagent for stabilizing vitamin B6 enzyme coenzyme in a reagent containing vitamin B6 enzyme and a coenzyme of the enzyme, wherein the vitamin B6 enzyme and the coenzyme of vitamin B6 enzyme are separately formulated as a composition during storage A method and a reagent characterized in that
6). Item 6. The method and reagent according to Item 5, wherein the vitamin B6 enzyme is tyrosine decarboxylase.
7). Item 6. The method and reagent according to Item 5, wherein the coenzyme is pyridoxal 5-phosphate.
8). Item 8. The method and reagent according to any one of Items 5 to 7, wherein the reagent using vitamin B6 enzyme is a tyrosine measuring reagent.
本発明によれば、補酵素が結合したビタミンB6酵素の活性発現を安定化させ、それを用いた試薬、例えばチロシン測定試薬の安定性、精密性を向上させることができる。 According to the present invention, the activity expression of the vitamin B6 enzyme to which a coenzyme is bound can be stabilized, and the stability and precision of a reagent using the enzyme, for example, a tyrosine measurement reagent can be improved.
本発明に用いられるビタミンB6酵素は、ピリドキサール5’-リン酸(PLP)またはピリドキサミン5’-リン酸(PMP)を補酵素とする酵素であれば特に限定されず、例えばアミノ酸脱炭酸酵素、アミノ酸ラセマーゼ、トランスアミナーゼなどのアミノ酸代謝に関係する酵素や筋のホスホリラーゼなどが挙げられる。さらに具体的にはチロシンデカルボキシラーゼ、アスパラギン酸アミノトランスフェラーゼなどが挙げられる。 The vitamin B6 enzyme used in the present invention is not particularly limited as long as it is an enzyme having pyridoxal 5'-phosphate (PLP) or pyridoxamine 5'-phosphate (PMP) as a coenzyme. For example, amino acid decarboxylase, amino acid Examples include enzymes related to amino acid metabolism such as racemase and transaminase, and muscle phosphorylase. More specifically, tyrosine decarboxylase, aspartate aminotransferase and the like can be mentioned.
本発明のビタミンB6酵素は、補酵素を脱塩等により除いたアポ化型酵素を使用してもよく、補酵素を結合したホロ化型酵素を使用してもよい。ビタミンB6酵素に100%補酵素が結合している場合(完全ホロ化型酵素)、補酵素をさらに添加する必要はないが、市場に流通しているホロ化型ビタミンB6酵素は、製造上或いは保存上の理由によりアポ化型酵素が混ざっている場合があるので、このような不完全型のホロ化型酵素も、本発明において補酵素と別々に処方することにより活性発現の安定化を実現できるビタミンB6酵素に包含される。 As the vitamin B6 enzyme of the present invention, an apo-enzyme obtained by removing a coenzyme by desalting or the like, or a holo-enzyme bound with a coenzyme may be used. When 100% coenzyme is bound to vitamin B6 enzyme (fully holoenzyme), it is not necessary to add additional coenzyme. Since apo-enzymes may be mixed for storage reasons, such incomplete holo-enzymes are also formulated separately from the coenzyme in the present invention to stabilize the activity expression. Included in the possible vitamin B6 enzyme.
本発明の試薬は、水溶液などの液体状態、凍結乾燥や粉末などの固体状態のいずれであっても良いが、一般に酵素などのタンパク質、補酵素の保存にとって条件の悪い液体状態(液状試薬、あるいは、凍結乾燥品を溶解した後の安定性維持)において効果がより発揮される。 The reagent of the present invention may be in a liquid state such as an aqueous solution or a solid state such as lyophilized or powdered, but is generally in a liquid state (liquid reagent or The effect is more exhibited in maintaining stability after dissolving the freeze-dried product).
保存温度は冷蔵条件、すなわち10℃以下凍らない温度以上、好ましくは4℃付近である。 The storage temperature is refrigerated conditions, that is, a temperature not exceeding 10 ° C. and freezing, preferably around 4 ° C.
本発明の好ましい実施形態において、ビタミンB6酵素と該ビタミンB6酵素の補酵素は、各々溶液として別々に処方され、使用時にこれらを合わせて使用する。ビタミンB6酵素と該ビタミンB6酵素の補酵素を溶液として処方する場合、そのpHは通常5〜10程度、好ましくはpH6〜8程度,より好ましくはpH6〜7.5程度である。該溶液は、緩衝液であるのが好ましい。緩衝液としては、リン酸緩衝液、トリス塩酸緩衝液などが好ましい。 In a preferred embodiment of the present invention, the vitamin B6 enzyme and the coenzyme of the vitamin B6 enzyme are each formulated separately as a solution, and are used together in use. When a vitamin B6 enzyme and a coenzyme of the vitamin B6 enzyme are formulated as a solution, the pH is usually about 5 to 10, preferably about pH 6 to 8, more preferably about pH 6 to 7.5. The solution is preferably a buffer. As the buffer solution, phosphate buffer solution, Tris-HCl buffer solution and the like are preferable.
本発明の安定化機序としては、不安定化要因である補酵素の劣化を酵素共存下で生じせしめないことにある。補酵素の劣化は主に光による酸化と考えられるが、本発明における補酵素の劣化要因は特に限定されない。 The stabilization mechanism of the present invention is to prevent coenzyme degradation, which is a destabilizing factor, from occurring in the presence of an enzyme. The degradation of the coenzyme is considered to be mainly due to oxidation by light, but the coenzyme degradation factor in the present invention is not particularly limited.
理論により拘束されることを望むものではないが、本発明者は、該ビタミンB6酵素とその補酵素を別々に処方することで、該ビタミンB6酵素の活性発現の安定化できる理由について、以下のように推測している。
補酵素の結合していないビタミンB6酵素(アポ型酵素)とその補酵素を1つのパーツに共存させると、保存中にビタミンB6酵素(アポ型酵素)とその補酵素が結合してホロ型酵素になる。
Although not wishing to be bound by theory, the present inventor has the following reason why the activity expression of the vitamin B6 enzyme can be stabilized by separately formulating the vitamin B6 enzyme and its coenzyme. I guess so.
Vitamin B6 enzyme (apo-type enzyme) that is not bound to coenzyme and its coenzyme coexist in one part, vitamin B6 enzyme (apo-type enzyme) and its coenzyme are combined during storage and holo-type enzyme become.
ホロ型酵素において補酵素が劣化した場合、新たに劣化していない補酵素を加えてもビタミンB6酵素の活性発現は低下したままである。これは、劣化した補酵素とビタミンB6酵素の置換が容易には起こらないためであると推測される。 When the coenzyme deteriorates in the holo-type enzyme, the activity expression of the vitamin B6 enzyme remains lowered even if a new coenzyme not deteriorated is added. This is presumably because the replacement of the degraded coenzyme with the vitamin B6 enzyme does not occur easily.
ビタミンB6酵素(アポ型酵素)とその補酵素を別々に(例えば別々のパーツに)処方した場合であっても、補酵素の一部の劣化はホロ型酵素と同様に起こり得るが、
ビタミンB6酵素(アポ型酵素)とその補酵素を使用直前に混合した場合、ビタミンB6酵素の活性発現は低下は見られず、該酵素の活性発現は安定化される。この現象の1つの解釈として、本発明者はビタミンB6酵素(アポ型酵素)は劣化した補酵素よりも劣化していない補酵素と選択的に結合するため、保存中に補酵素の一部が劣化したとしても、ビタミンB6酵素(ホロ型酵素)の活性低下は起こらないと考えている。
Even when vitamin B6 enzyme (apo-type enzyme) and its coenzyme are formulated separately (for example, in separate parts), some degradation of the coenzyme can occur in the same way as the holo-type enzyme,
When a vitamin B6 enzyme (apo-type enzyme) and its coenzyme are mixed immediately before use, the activity expression of the vitamin B6 enzyme is not reduced, and the activity expression of the enzyme is stabilized. One interpretation of this phenomenon is that the present inventors selectively bind vitamin B6 enzyme (apo-type enzyme) to an undegraded coenzyme rather than a degraded coenzyme. Even if it deteriorates, it is considered that the activity of vitamin B6 enzyme (holo-type enzyme) does not decrease.
本発明は、チロシン測定試薬を調製するときに特に有利である。 The present invention is particularly advantageous when preparing a tyrosine measurement reagent.
チロシン測定試薬を使用したチロシンの測定は、例えば以下のようにして実施することができる: Measurement of tyrosine using a tyrosine measuring reagent can be performed, for example, as follows:
*EHSPT:N-エチル-N-(2-ヒドロキシ-3-スルホプロピル)-m-トルイジン
具体的には、検体中のチロシンにチロシンデカルボキシラーゼを作用させるとチラミンとCO2に変換され、次いでチラミンオキシダーゼを作用させると、4−ヒドロキシフェニルアセトアルデヒドとNH3とH2O2に分解される。生成したH2O2をペルオキシダーゼの作用下に4-アミノアンチピリンとEHSPTを酸化縮合させ、得られたキノン色素を吸光度測定し、チロシン量を測定することができる。
* EHSPT: N-ethyl-N- (2-hydroxy-3-sulfopropyl) -m-toluidine Specifically, when tyrosine decarboxylase is allowed to act on tyrosine in a sample, it is converted to tyramine and CO2, and then tyramine oxidase Is decomposed into 4-hydroxyphenylacetaldehyde, NH 3 and H 2 O 2 . The produced H 2 O 2 can be oxidized and condensed with 4-aminoantipyrine and EHSPT under the action of peroxidase, the absorbance of the resulting quinone dye can be measured, and the amount of tyrosine can be measured.
本発明の特に好ましい実施形態の一つにおいて、チロシン測定試薬は、以下のものを含む:
・ ビタミンB6酵素(第一試薬にペルオキシダーゼ、チラミンオキシダーゼ、第二試薬はチラミンデカルボキシラーゼ);
・ 補酵素(ビタミンB6)
・ ペルオキシダーゼの存在下で発生した過酸化水素と反応して可視化される色素系(例えば第一試薬にN-エチル(2-ヒドロキシ-3-スルホプロピル)-m-トルイジン、第二試薬に4-アミノアンチピリン);及び
・ 緩衝剤。
In one particularly preferred embodiment of the present invention, the tyrosine measurement reagent comprises the following:
Vitamin B6 enzyme (peroxidase, tyramine oxidase as the first reagent, tyramine decarboxylase as the second reagent);
・ Coenzyme (vitamin B6)
A dye system that is visualized by reaction with hydrogen peroxide generated in the presence of peroxidase (eg, N-ethyl (2-hydroxy-3-sulfopropyl) -m-toluidine as the first reagent, 4- Aminoantipyrine); and buffering agents.
酵素は、自動分析機(例えば日立7170型自動分析機)で測定できるように第一試薬と第二試薬に分けることが望ましく、このように二つに分けることで試薬の保存安定性をさらに向上させることができる。また、補酵素と酵素は、別々のパーツに分けられて処方され、測定前に混合される。第一試薬と第二試薬並びに補酵素は、別々のバイアルに保存されていてもよく、使用時に溶解液(通常は緩衝液)に溶解させて使用することもできる。各パーツに処方する組成の組合せは、反応原理から第一試薬のチラミンオキシダーゼ、第二試薬のチロシンデカルボキシラーゼ、並びに補酵素は必須であるが、そのほかの試薬成分は、共存時の安定性等を考慮して適宜設定することができる。
本発明で用いられるビタミンB6酵素の起原は特に限定されず、活性発現や構造の維持などに可逆的に補酵素を必要とするものであれば、微生物、植物または動物のいずれの起原のものも用いることが可能である。これらは種々の市販のものを使用することができる。或いは公知の方法によって該酵素を生産する細胞(微生物など)を培養し得られた培養物を精製することによっても入手できる。さらに、小麦胚芽抽出物などを用いた無細胞蛋白合成系を用いて製造することもできる。また、公知の方法によって、上記により得られた酵素のアミノ酸配列を改変したり、化学修飾を行ったものも、活性発現や構造の維持などに可逆的に電解質を必要とするものであれば、何ら問題なく使用できる。或いは、天然の状態ではもともと活性発現や構造の維持などに電解質を必要としなかった酵素に公知の方法によって改変を加えて電解質を必要としたものも本発明に用いることができる。
It is desirable to divide the enzyme into the first reagent and the second reagent so that the enzyme can be measured by an automatic analyzer (for example, Hitachi 7170 type automatic analyzer). In this way, the storage stability of the reagent is further improved. Can be made. Also, the coenzyme and the enzyme are prescribed in separate parts and mixed before measurement. The first reagent, the second reagent, and the coenzyme may be stored in separate vials, or can be used by dissolving in a solution (usually a buffer) at the time of use. The combination of the compositions prescribed for each part requires the first reagent tyramine oxidase, the second reagent tyrosine decarboxylase, and the coenzyme from the reaction principle, but other reagent components have stability when coexisting. It can be set as appropriate in consideration.
The origin of the vitamin B6 enzyme used in the present invention is not particularly limited, and any origin of microorganisms, plants, or animals may be used as long as it requires a coenzyme reversibly for expression of activity and maintenance of structure. A thing can also be used. Various commercially available products can be used. Alternatively, it can also be obtained by purifying a culture obtained by culturing cells (such as microorganisms) that produce the enzyme by a known method. Furthermore, it can also be produced using a cell-free protein synthesis system using wheat germ extract or the like. In addition, if the amino acid sequence of the enzyme obtained as described above is modified by a known method or chemically modified, it can be reversibly required for the expression of activity or maintenance of the structure. Can be used without any problems. Alternatively, an enzyme that does not require an electrolyte for its activity expression or maintenance of its structure in a natural state by modifying it by a known method and requires an electrolyte can also be used in the present invention.
ペルオキシダーゼの存在下で発生した過酸化水素と反応して可視化される色素系としては、酸化系発色試薬、還元系発色試薬、トリンダー試薬及びそのカプラー等が例示される。酸化系発色試薬としては、
ヘキサ(2−ヒドロキシ−3−スルホプロピル)−4,4,4−トリアミノトリフェニルメタン、
ヘキサ(3−スルホプロピル)−4,4,4−トリアミノトリフェニルメタン、
ビス(2−ヒドロキシ−3−スルホプロピル)トルイジン等が挙げられる。
Examples of the dye system that is visualized by reacting with hydrogen peroxide generated in the presence of peroxidase include an oxidizing coloring reagent, a reducing coloring reagent, a Trinder reagent, and a coupler thereof. As an oxidative coloring reagent,
Hexa (2-hydroxy-3-sulfopropyl) -4,4,4-triaminotriphenylmethane,
Hexa (3-sulfopropyl) -4,4,4-triaminotriphenylmethane,
Bis (2-hydroxy-3-sulfopropyl) toluidine and the like can be mentioned.
還元系発色試薬としては、例えばテトラゾリウム塩類が挙げられ、INT,MTT,TB,WST−1,WST−3,WST−5等が挙げられ、1−m−PMS等の電子キャリアーと組み合わせて用いられる。トリンダー試薬としては、N−エチル−N−スルホプロピル−m−アニシジン、N−エチル−N−スルホプロピルアニリン、N−エチル−N−スルホプロピル−3,5−ジメトキシアニリン、N−スルホプロピル−3,5−ジメチルアニリン、N−エチル−N−スルホプロピル−3,5−ジメチルアニリン、N−エチル−N−スルホプロピル−m−トルイジン、N−エチル−N−(2−ヒドロキシ−3−スルホプロピル)−m−アニシジン、N−エチル−N−(2−ヒドロキシ−3−スルホプロピル)−アニリン、N−エチル−N−(2−ヒドロキシ−3−スルホプロピル)−3,5−ジメトキシアニリン、N−エチル−N−(2−ヒドロキシ−3−スルホプロピル)−3,5−ジメメチルアニリン、N−エチル−N−(2−ヒドロキシ−3−スルホプロピル)−m−トルイジン、N−スルホプロピルアニリンが挙げられる。そのカプラーとしては、4-アミノアンチピリン、MBTH等が挙げられる。 Examples of the reducing coloring reagent include tetrazolium salts such as INT, MTT, TB, WST-1, WST-3, and WST-5, and are used in combination with an electron carrier such as 1-m-PMS. . As the Trinder reagent, N-ethyl-N-sulfopropyl-m-anisidine, N-ethyl-N-sulfopropylaniline, N-ethyl-N-sulfopropyl-3,5-dimethoxyaniline, N-sulfopropyl-3 , 5-dimethylaniline, N-ethyl-N-sulfopropyl-3,5-dimethylaniline, N-ethyl-N-sulfopropyl-m-toluidine, N-ethyl-N- (2-hydroxy-3-sulfopropyl) ) -M-anisidine, N-ethyl-N- (2-hydroxy-3-sulfopropyl) -aniline, N-ethyl-N- (2-hydroxy-3-sulfopropyl) -3,5-dimethoxyaniline, N -Ethyl-N- (2-hydroxy-3-sulfopropyl) -3,5-dimethylmethylaniline, N-ethyl-N- (2-hydroxy-3 Sulfopropyl)-m-toluidine, include N- sulfopropyl aniline. Examples of the coupler include 4-aminoantipyrine and MBTH.
本発明に使用される緩衝剤としては、特に限定されないが、トリス緩衝剤、クエン酸緩衝剤、リン酸緩衝剤、ほう酸ホウ砂緩衝剤、GOOD緩衝剤等が挙げられる。なかでもトリス緩衝剤、クエン酸緩衝剤、ほう酸ホウ砂緩衝剤、リン酸緩衝剤、は濃度、温度によってpHが変動しやすいが、安価であるという利点がある。また、GOOD緩衝剤はMES,Bis−Tris,ADA,ACES,BES,PIPES,MOPS,TES,HEPES,Tricine,Bicine,POPSO,TAPS,CHES,CAPSなどが例示される。 Although it does not specifically limit as a buffering agent used for this invention, A tris buffer, a citrate buffer, a phosphate buffer, a borate borax buffer, a GOOD buffer, etc. are mentioned. Among these, Tris buffer, citrate buffer, borate buffer, and phosphate buffer have the advantage of being inexpensive, although the pH is likely to vary depending on the concentration and temperature. Examples of the GOOD buffer include MES, Bis-Tris, ADA, ACES, BES, PIPES, MOPS, TES, HEPES, Tricine, Bicine, POPSO, TAPS, CHES, and CAPS.
以下、本発明を実施例により具体的に説明する。なお、本発明は実施例により特に限定されるものではない。
(実施例1)
下記のチロシン測定試薬を10℃、7日間保存し、チロシンデカルボキシラーゼ(アポ化型酵素)の残存活性(調製直後の活性値に対する保存後の活性値の割合)を検討した。比較例では、下記組成より第一試薬のピリドキサール5-リン酸エステルを添加せず、第二試薬にピリドキサール5-リン酸エステル 40μmol/L添加した試薬を同様に検討した。
(試薬の調製)
下記組成からなるチロシン測定試薬を調製した。
第一試薬
マックィルバイン緩衝液 50mM pH6.0
トリトンX−100 1g/L
TOOS 1g/L
フラビンアデニンジヌクレオチド2Na塩 8μmol/L
ペルオキシダーゼ(東洋紡社製PEO−301) 3U/mL
アスコルビン酸オキシダーゼ(東洋紡社製ASO−311) 1U/mL
チラミンオキシダーゼ(東洋紡社製TYO−301) 0.3U/mL
ピリドキサール5-リン酸エステル 10μmol/L
第ニ試薬
マックィルバイン緩衝液 50mM pH6.0
トリトンX−100 1g/L
4−アミノアンチピリン 0.3g/L
チロシンデカルボキシラーゼ 1.2U/mL
Hereinafter, the present invention will be specifically described by way of examples. In addition, this invention is not specifically limited by an Example.
Example 1
The following tyrosine measurement reagents were stored at 10 ° C. for 7 days, and the remaining activity of tyrosine decarboxylase (apo-type enzyme) (ratio of activity value after storage to activity value immediately after preparation) was examined. In the comparative example, a reagent prepared by adding 40 μmol / L of pyridoxal 5-phosphate to the second reagent without adding the first reagent, pyridoxal 5-phosphate, was examined in the same manner.
(Preparation of reagents)
A tyrosine measuring reagent having the following composition was prepared.
First reagent Mcylvine buffer 50 mM pH 6.0
Triton X-100 1g / L
TOOS 1g / L
Flavin adenine dinucleotide 2Na salt 8 μmol / L
Peroxidase (Toyobo PEO-301) 3 U / mL
Ascorbate oxidase (Toyobo ASO-311) 1 U / mL
Tyramine oxidase (Toyobo TYO-301) 0.3 U / mL
Pyridoxal 5-phosphate ester 10 μmol / L
Second reagent Mcylvine buffer 50 mM pH 6.0
Triton X-100 1g / L
4-Aminoantipyrine 0.3g / L
Tyrosine decarboxylase 1.2U / mL
結果: 表1に示す。比較例では10℃、7日後のチロシンデカルボキシラーゼの残存活性は59%まで活性が低下するのに対し、実施例では保存後も90%以上の良好な安定性を示した。
(実施例2)
実施例1のチロシン測定試薬を10℃、11日間保存し、下記の測定法にて試料として精製水、200μmol/Lチロシン水溶液を測定し200μmol/Lチロシン水溶液測定吸光度から精製水測定吸光度を差引いた吸光度(感度)を算出し調製直後のその吸光度と比較し相対パーセントを求めた。比較例では、下記組成より第一試薬のピリドキサール5-リン酸エステルを添加せず、第二試薬にピリドキサール5-リン酸エステル 40μmol/L添加した試薬を同様に検討した。
(測定法)
日立7170形自動分析機を用いた。試料2.5μLに第一試薬 200μL添加し37℃にて5分間インキュベーションし第一反応とした。その後第二試薬を50μL添加し5分間インキュベーションし第二反応とした。第一反応および第二反応の吸光度を液量補正した各吸光度の差をとる2ポイントエンド法で570nmにおける吸光度を測定した。
結果は、精製水および200μmol/LL-チロシン水溶液の測定吸光度より算出しチロシン濃度として求めた。
Results: Shown in Table 1. In the comparative example, the remaining activity of tyrosine decarboxylase after 7 days at 10 ° C. decreased to 59%, whereas in the examples, good stability of 90% or more was exhibited after storage.
(Example 2)
The tyrosine measuring reagent of Example 1 was stored at 10 ° C. for 11 days, purified water and 200 μmol / L tyrosine aqueous solution were measured as samples by the following measurement method, and the purified water measured absorbance was subtracted from the 200 μmol / L tyrosine aqueous solution measured absorbance. The absorbance (sensitivity) was calculated and compared with the absorbance immediately after preparation to determine the relative percentage. In the comparative example, a reagent prepared by adding 40 μmol / L of pyridoxal 5-phosphate to the second reagent without adding the first reagent, pyridoxal 5-phosphate, was examined in the same manner.
(Measurement method)
A Hitachi 7170 automatic analyzer was used. First reaction was performed by adding 200 μL of the first reagent to 2.5 μL of the sample and incubating at 37 ° C. for 5 minutes. Thereafter, 50 μL of the second reagent was added and incubated for 5 minutes to form a second reaction. The absorbance at 570 nm was measured by a two-point end method in which the absorbances of the first reaction and the second reaction were corrected for the liquid volume and the difference between the absorbances was taken.
The result was calculated from the measured absorbance of purified water and 200 μmol / LL-tyrosine aqueous solution, and obtained as the tyrosine concentration.
結果 表2に示す。比較例では10℃、11日後の感度が52%まで低下するのに対し、実施例では保存後もほぼ100%であり良好な安定性を示した。
(実施例3)
実施例1のチロシン測定試薬の調製直後および10℃、7日間保存した試薬、各々について、実施例2に記載の測定法にて同時再現性を検討した。同時再現性は市販管理血清QAPトロールIIX(シスメックス社)にL-チロシンを終濃度100μmol/Lになるように添加したものを試料とし繰返しn=20で測定し変動係数CV(%)を算出した。比較例では、下記組成より第一試薬のピリドキサール5-リン酸エステルを添加せず、第二試薬にピリドキサール5-リン酸エステル 40μmol/L添加した試薬を同様に検討した。
Results are shown in Table 2. In the comparative example, the sensitivity after 11 days at 10 ° C. decreased to 52%, whereas in the example, after storage, it was almost 100%, indicating good stability.
(Example 3)
Immediately after the preparation of the tyrosine measurement reagent of Example 1 and each of the reagents stored at 10 ° C. for 7 days, the simultaneous reproducibility was examined by the measurement method described in Example 2. The simultaneous reproducibility was calculated by repeatedly measuring n = 20 and adding a coefficient of variation CV (%) to a sample prepared by adding L-tyrosine to commercial control serum QAP Troll IIX (Sysmex) to a final concentration of 100 μmol / L. . In the comparative example, a reagent prepared by adding 40 μmol / L of pyridoxal 5-phosphate to the second reagent without adding the first reagent, pyridoxal 5-phosphate, was examined in the same manner.
結果 表3に示す。比較例では調製直後に対し10℃、7日後の変動係数が悪化したのに対し、実施例では保存後も調製直後とほぼ同等であり良好な安定性、精密性を示した。 Results are shown in Table 3. In the comparative example, the coefficient of variation after 10 days at 10 ° C. deteriorated immediately after the preparation, whereas in the example, after storage, it was almost the same as that immediately after the preparation and showed good stability and precision.
本発明のビタミンB6酵素の安定化法は、本酵素を用いた試薬、体外診断用医薬品などの用途分野に利用することができ、産業界に寄与することが大である The method for stabilizing the vitamin B6 enzyme of the present invention can be used in fields of application such as reagents and in vitro diagnostics using the enzyme, and contributes greatly to the industry.
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004264473A JP4797349B2 (en) | 2004-09-10 | 2004-09-10 | Method of stabilizing reagent using vitamin B6 enzyme and reagent |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004264473A JP4797349B2 (en) | 2004-09-10 | 2004-09-10 | Method of stabilizing reagent using vitamin B6 enzyme and reagent |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2006075111A JP2006075111A (en) | 2006-03-23 |
JP4797349B2 true JP4797349B2 (en) | 2011-10-19 |
Family
ID=36155082
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2004264473A Expired - Lifetime JP4797349B2 (en) | 2004-09-10 | 2004-09-10 | Method of stabilizing reagent using vitamin B6 enzyme and reagent |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP4797349B2 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007289097A (en) * | 2006-04-26 | 2007-11-08 | Toyobo Co Ltd | Liquid reagent for determination of molar ratio of total branched-chain amino acid/tyrosine |
JP5326331B2 (en) * | 2008-04-04 | 2013-10-30 | 東洋紡株式会社 | Method for stabilizing tyramine oxidase and composition thereof |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0698036B2 (en) * | 1986-10-20 | 1994-12-07 | 小野薬品工業株式会社 | Selective quantification of amino acids |
US5116728A (en) * | 1990-07-20 | 1992-05-26 | Em Diagnostic Systems, Incorporated | Reagents for co2 detection |
JP3632990B2 (en) * | 1994-06-09 | 2005-03-30 | 日立化成工業株式会社 | Chemiluminescence measuring reagent and chemiluminescence measuring method |
JP2001204493A (en) * | 2000-01-30 | 2001-07-31 | Kainosu:Kk | Assaying reagent and assaying method |
JP3674450B2 (en) * | 2000-03-21 | 2005-07-20 | 日東紡績株式会社 | Reagent for GPT measurement |
JP2003125784A (en) * | 2001-10-29 | 2003-05-07 | Higeta Shoyu Co Ltd | New tyrosine decarboxylase |
-
2004
- 2004-09-10 JP JP2004264473A patent/JP4797349B2/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
JP2006075111A (en) | 2006-03-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8080423B2 (en) | Reagent containing protease reaction promoter and/or colorant stabilizer | |
JPWO2007037419A1 (en) | Method for simultaneous fractionation and quantification of two measurement objects in biological samples | |
JPH11504808A (en) | Measurement of glycated protein | |
EP1813680B1 (en) | Compositions for lipase activity determination and method of determining activity | |
JP2015204825A (en) | L-glutamine measurement kit | |
JP4889396B2 (en) | Method for stabilizing leuco dyes | |
JP2021061802A (en) | Method for measuring l-glutamine, and kit for the same | |
US5804402A (en) | Reagent | |
JPH04287695A (en) | Composition for analyzing ethanol | |
JPH0670798A (en) | Uric acid measurement reagent composition | |
WO2013161676A1 (en) | Method for stabilizing cholesterol oxidase | |
JP4797349B2 (en) | Method of stabilizing reagent using vitamin B6 enzyme and reagent | |
JP5017614B2 (en) | Method and reagent for measuring substance to be measured in sample, method for suppressing nonspecific color development, and nonspecific color development inhibitor | |
JP4257568B2 (en) | Biological component measurement method and reagent composition used therefor | |
EP0100217A2 (en) | Process for quantitative determination of substrate treated with oxidase | |
JP4426725B2 (en) | Homocysteine measurement method | |
EP1595950B1 (en) | Method of measuring homocysteine | |
BR112014028748B1 (en) | METHODS FOR STABILIZING AND PRESERVING ASCORBIC ACID OXIDASE | |
JPWO2018012607A1 (en) | Reaction accelerator | |
JP3674450B2 (en) | Reagent for GPT measurement | |
JP5326331B2 (en) | Method for stabilizing tyramine oxidase and composition thereof | |
JP4651237B2 (en) | Method and reagent for stabilizing reduced nicotinamide adenine dinucleotides | |
JP5326324B2 (en) | Method for stabilizing tyramine oxidase and composition thereof | |
JP2000236897A (en) | Measuring method and measuring reagent of enzyme inhibitor | |
JP4029609B2 (en) | Biological component measurement method and reagent kit used therefor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20070419 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100407 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110412 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110613 |
|
TRDD | Decision of grant or rejection written | ||
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20110614 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20110705 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20110718 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140812 Year of fee payment: 3 |
|
R151 | Written notification of patent or utility model registration |
Ref document number: 4797349 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R151 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140812 Year of fee payment: 3 |
|
S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
S533 | Written request for registration of change of name |
Free format text: JAPANESE INTERMEDIATE CODE: R313533 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |